Brought to you by 
Myovant nets $135mm through public offering
17 Dec 2020
Executive Summary
Myovant Sciences Inc. (therapies for women's health and prostate cancer) netted $135mm through a public offering of 17.4mm common shares (including the overallotment) at $8.25. Funds will support ongoing Phase III trials with lead candidate relugolix (the LIBERTY trial for uterine fibroids and heavy menstrual bleeding, and the HERO study for advanced prostate cancer), and will also be used to fund potential regulatory filings for the project.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Myovant nets $135mm through public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice